Wells Fargo downgraded Cabaletta Bio (CABA) to Equal Weight from Overweight with a price target of $6, down from $12. The firm does not think the shares can work “from depressed levels” until Cabalettais able to address its capital overhang and amass enough data, including on durability, for investors to get more constructive on the story. The CABA-201 updates in 2025 are likely to be incremental, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA: